| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1028032153 |
| P356 | DOI | 10.1038/NATURE09495 |
| P3181 | OpenCitations bibliographic resource ID | 1332985 |
| P698 | PubMed publication ID | 20881963 |
| P50 | author | Eva Gonzalez-Suarez | Q56480850 |
| P2093 | author name string | Jon Jones | |
| Robert Miller | |||
| William C Dougall | |||
| Jan Pinkas | |||
| Dan Branstetter | |||
| Allison P Jacob | |||
| Martine P Roudier-Meyer | |||
| Ryan Erwert | |||
| P2860 | cites work | A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 |
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development | Q28142247 | ||
| Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis | Q28291864 | ||
| Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin | Q28294196 | ||
| IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development | Q28508430 | ||
| Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease | Q28570541 | ||
| The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse | Q28585870 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer | Q33181504 | ||
| Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. | Q33733718 | ||
| The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting | Q33860801 | ||
| Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial | Q34208463 | ||
| Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice | Q34342812 | ||
| Progesterone involvement in breast development and tumorigenesis--as revealed by progesterone receptor "knockout" and "knockin" mouse models | Q35605000 | ||
| RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini | Q35641868 | ||
| Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours | Q35769514 | ||
| Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors | Q35906418 | ||
| A paracrine role for the epithelial progesterone receptor in mammary gland development | Q36064196 | ||
| Progesterone induces adult mammary stem cell expansion | Q42471079 | ||
| Control of mammary stem cell function by steroid hormone signalling. | Q43103606 | ||
| Increased risk of recurrence after hormone replacement therapy in breast cancer survivors | Q43775712 | ||
| Lack of ductal development in the absence of functional estrogen receptor alpha delays mammary tumor formation induced by transgenic expression of ErbB2/neu | Q43998970 | ||
| Postmenopausal hormone therapy and change in mammographic density | Q44267695 | ||
| Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. | Q54788141 | ||
| Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast | Q73276429 | ||
| Progestins and breast cancer | Q80134766 | ||
| P433 | issue | 7320 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | carcinogenesis | Q1637543 |
| P304 | page(s) | 103-7 | |
| P577 | publication date | 2010-11-04 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis | |
| P478 | volume | 468 |
| Q24338768 | A NIK-IKKα module expands ErbB2-induced tumor-initiating cells by stimulating nuclear export of p27/Kip1 |
| Q35029498 | A local basis for progesterone action during mammary tumorigenesis - no longer RANK and file |
| Q33633141 | A new strategy for selective targeting of progesterone receptor with passive antagonists |
| Q35659971 | Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors |
| Q35794436 | Aberrant activation of NF-κB signaling in mammary epithelium leads to abnormal growth and ductal carcinoma in situ |
| Q37706111 | Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer |
| Q91733167 | Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial |
| Q99548897 | Alterations in Progesterone Receptor Isoform Balance in Normal and Neoplastic Breast Cells Modulates the Stem Cell Population |
| Q34160418 | Amphiregulin mediates estrogen, progesterone, and EGFR signaling in the normal rat mammary gland and in hormone-dependent rat mammary cancers |
| Q26863493 | Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences |
| Q37923343 | Anti-cancer actions of denosumab |
| Q39351791 | Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors |
| Q35150939 | Apigenin prevents development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats |
| Q35853244 | Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity |
| Q33798713 | BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells |
| Q28265584 | Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab |
| Q38471535 | Benefits and risks during HRT: main safety issue breast cancer |
| Q35000798 | Biology of breast cancer in young women |
| Q34366449 | Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond |
| Q37946408 | Biomarkers for breast cancer stem cells: the challenges ahead |
| Q36196602 | Bone structural components regulating sites of tumor metastasis |
| Q90289461 | Bone-Targeted Agents in Breast Cancer: Do We Now Have All the Answers? |
| Q48110513 | Bone-Targeted Therapies in Cancer-Induced Bone Disease |
| Q59035695 | Bone-disease drug could treat breast cancer |
| Q28087676 | Bone-targeted therapy in metastatic breast cancer - all well-established knowledge? |
| Q37973821 | Breast-cancer stem cells-beyond semantics |
| Q42586718 | CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany |
| Q26775406 | Caldecrin: A pancreas-derived hypocalcemic factor, regulates osteoclast formation and function |
| Q38991293 | Can we prevent BRCA1-associated breast cancer by RANKL inhibition? |
| Q36884628 | Cancer to bone: a fatal attraction |
| Q39014552 | Cell lineage determinants as regulators of breast cancer metastasis |
| Q35798899 | Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion |
| Q35609448 | Chronic stress, sympathetic activation and skeletal metastasis of breast cancer cells |
| Q38682103 | Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort |
| Q57796276 | Circulating Receptor Activator of Nuclear Factor-κB (RANK), RANK ligand (RANKL) and Mammographic Density in Premenopausal Women |
| Q92318039 | Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers |
| Q37800534 | Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis |
| Q36905719 | Clinical prognostic significance and pro-metastatic activity of RANK/RANKL via the AKT pathway in endometrial cancer |
| Q39036670 | Clinical significance of CYLD downregulation in breast cancer |
| Q39104687 | Co-expression of CD44+/RANKL+ tumor cells in the carcinogenesis of oral squamous cell carcinoma |
| Q91651961 | Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas |
| Q36119454 | Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer. |
| Q33975619 | Concise review: breast cancer stem cells: regulatory networks, stem cell niches, and disease relevance |
| Q42439949 | Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis. |
| Q37905720 | Contribution of bone tissue modulus to breast cancer metastasis to bone |
| Q33775316 | Correlation of mammographic density and serum calcium levels in patients with primary breast cancer |
| Q36240642 | Cripto-1 ablation disrupts alveolar development in the mouse mammary gland through a progesterone receptor-mediated pathway. |
| Q38938523 | Curcumin analog UBS109 prevents bone marrow osteoblastogenesis and osteoclastogenesis disordered by coculture with breast cancer MDA-MB-231 bone metastatic cells in vitro |
| Q37665648 | DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations |
| Q93016733 | Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study |
| Q37965768 | Denosumab and the current status of bone-modifying drugs in breast cancer |
| Q37970800 | Denosumab for the management of bone disease in patients with solid tumors |
| Q38040123 | Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors |
| Q37986124 | Denosumab for treatment of breast cancer bone metastases and beyond |
| Q34381979 | Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. |
| Q37974570 | Denosumab in patients with cancer-a surgical strike against the osteoclast |
| Q36040881 | Denosumab treatment for fibrous dysplasia |
| Q37467278 | Denosumab: A comprehensive review |
| Q36277837 | Denosumab: a new option in the treatment of bone metastases from urological cancers |
| Q54186456 | Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer. |
| Q34430545 | Differential regulation of breast cancer-associated genes by progesterone receptor isoforms PRA and PRB in a new bi-inducible breast cancer cell line |
| Q52662141 | Disrupting Na⁺, HCO₃⁻-cotransporter NBCn1 (Slc4a7) delays murine breast cancer development. |
| Q36924384 | ER and PR signaling nodes during mammary gland development |
| Q84449609 | Effects of RANKL on the thymic medulla |
| Q37441693 | Effects of RANKL-Targeted Therapy in Immunity and Cancer |
| Q60921418 | Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis |
| Q34434910 | Elevated GH/IGF-I promotes mammary tumors in high-fat, but not low-fat, fed mice |
| Q35686250 | Emerging candidates in breast cancer stem cell maintenance, therapy resistance and relapse. |
| Q38538263 | Emerging drugs for the treatment of bone metastasis. |
| Q38216322 | Endocrine aspects of bone metastases |
| Q36121103 | Epithelial cell identity in hyperplastic precursors of breast cancer |
| Q57881796 | Evidence for a link between TNFRSF11A and risk of breast cancer |
| Q42972436 | From bone to breast and back - the bone cytokine RANKL and breast cancer |
| Q92076003 | From latency to overt bone metastasis in breast cancer: potential for treatment and prevention |
| Q35659426 | From the ranks of mammary progesterone mediators, RANKL takes the spotlight |
| Q38019409 | Genes associate with abnormal bone cell activity in bone metastasis |
| Q30534404 | Genetic polymorphism of the OPG gene associated with breast cancer |
| Q90442956 | Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond |
| Q35029509 | High hopes for RANKL: will the mouse model live up to its promise? |
| Q38226179 | Hormonal regulation of the immune microenvironment in the mammary gland |
| Q47635634 | Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study |
| Q36903215 | Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium |
| Q36033261 | Identification of NOG as a specific breast cancer bone metastasis-supporting gene |
| Q36924500 | Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration |
| Q47666371 | Immunohistochemical and quantitative RT-PCR methods to assess RANK expression in normal and neoplastic canine mammary gland. |
| Q37000157 | Impact of denosumab on bone mass in cancer patients |
| Q38562815 | Impact of progesterone on stem/progenitor cells in the human breast |
| Q44010610 | Impact of recent parity on histopathological tumor features and breast cancer outcome in premenopausal Japanese women |
| Q47681521 | Increased breast tissue receptor activator of nuclear factor-κB ligand (RANKL) gene expression is associated with higher mammographic density in premenopausal women |
| Q36732552 | Inflammation and Hras signaling control epithelial-mesenchymal transition during skin tumor progression. |
| Q29620242 | Inflammation meets cancer, with NF-κB as the matchmaker |
| Q35040517 | Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts |
| Q34102993 | Integrin αvβ3 drives slug activation and stemness in the pregnant and neoplastic mammary gland |
| Q37829690 | Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications |
| Q60456013 | Joining the RANKs |
| Q47250561 | Key Factors in Breast Cancer Dissemination and Establishment at the Bone: Past, Present and Future Perspectives. |
| Q54200830 | LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. |
| Q36662452 | Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode. |
| Q46194866 | Lgr6 is a stem cell marker in mouse skin squamous cell carcinoma. |
| Q28727655 | Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab |
| Q34396516 | Loss of SFRP1 promotes ductal branching in the murine mammary gland |
| Q57112976 | Mammary Stem Cells and Breast Cancer Stem Cells: Molecular Connections and Clinical Implications |
| Q24629797 | Mammary gland development |
| Q27003345 | Mammary stem cells and the differentiation hierarchy: current status and perspectives |
| Q47111770 | Mechanism of M-cell differentiation accelerated by proliferation of indigenous bacteria in rat Peyer's patches |
| Q91388562 | Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer |
| Q42380563 | MiR-31 promotes mammary stem cell expansion and breast tumorigenesis by suppressing Wnt signaling antagonists |
| Q33631557 | Minireview: Progesterone Regulation of Proliferation in the Normal Human Breast and in Breast Cancer: A Tale of Two Scenarios? |
| Q38245726 | Modeling cutaneous squamous carcinoma development in the mouse |
| Q38155200 | Multifunctional properties of RANKL/RANK in cell differentiation, proliferation and metastasis |
| Q57652753 | Multimodal Treatment of Bone Metastasis-A Surgical Perspective |
| Q60946525 | Mutations and Breast Cancer Prevention |
| Q37431321 | NF-kappaΒ-inducing kinase regulates stem cell phenotype in breast cancer. |
| Q37995696 | NF-κB and the link between inflammation and cancer |
| Q35608668 | NF-κB, stem cells and breast cancer: the links get stronger |
| Q26853017 | Nuclear receptors in bone physiology and diseases |
| Q57183997 | Nutrition and the biology of human ageing: Bone health & osteoporosis / sarcopenia / immune deficiency |
| Q41135180 | OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer |
| Q35572441 | Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection |
| Q47944184 | Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems. |
| Q92668034 | Osteoimmunology: evolving concepts in bone-immune interactions in health and disease |
| Q36252676 | Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers |
| Q36273402 | Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort |
| Q33636789 | Perinatal exposure to bisphenol a increases adult mammary gland progesterone response and cell number. |
| Q36463697 | Periodontal Disease and Breast Cancer: Prospective Cohort Study of Postmenopausal Women |
| Q96577047 | Personalized early detection and prevention of breast cancer: ENVISION consensus statement |
| Q64104436 | Plasma RANKL levels are not associated with breast cancer risk in and mutation carriers |
| Q37699313 | Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q42013702 | Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patients |
| Q38833288 | Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression |
| Q42413676 | Potential suppressive effects of gentian violet on human breast cancer MDA-MB-231 cells in vitro: Comparison with gemcitabine |
| Q92885772 | Prediction of Bone Metastasis in Inflammatory Breast Cancer Using a Markov Chain Model |
| Q38669803 | Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment |
| Q26799158 | Progesterone and Overlooked Endocrine Pathways in Breast Cancer Pathogenesis |
| Q35205643 | Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. |
| Q43643928 | Progesterone drives mammary secretory differentiation via RankL-mediated induction of Elf5 in luminal progenitor cells. |
| Q33998721 | Progesterone receptor action: defining a role in breast cancer |
| Q37249108 | Progesterone receptor and Stat5 signaling cross talk through RANKL in mammary epithelial cells |
| Q90412314 | Progesterone receptor integrates the effects of mutated MED12 and altered DNA methylation to stimulate RANKL expression and stem cell proliferation in uterine leiomyoma |
| Q35784828 | Progesterone regulation of stem and progenitor cells in normal and malignant breast |
| Q38109029 | Progesterone signalling in breast cancer: a neglected hormone coming into the limelight |
| Q39101500 | Progesterone stimulates proliferation and promotes cytoplasmic localization of the cell cycle inhibitor p27 in steroid receptor positive breast cancers. |
| Q36547484 | Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties |
| Q51042996 | Progesterone/RANKL is a major regulatory axis in the human breast. |
| Q21092903 | Progestin effects on cell proliferation pathways in the postmenopausal mammary gland |
| Q38572022 | Progestogens and risk of breast cancer: a link between bone and breast? |
| Q43142242 | Prospects of adjuvant RANKL inhibition in breast cancer? |
| Q38691526 | RANK as a therapeutic target in cancer. |
| Q52877576 | RANK expression as a prognostic and predictive marker in breast cancer. |
| Q39055979 | RANK expression on breast cancer cells promotes skeletal metastasis |
| Q39670403 | RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. |
| Q33895612 | RANK rs1805034 T>C polymorphism is associated with susceptibility of esophageal cancer in a Chinese population |
| Q64939796 | RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review. |
| Q38804090 | RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines |
| Q26747442 | RANK-RANKL signalling in cancer |
| Q88911025 | RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF-κB activation and EGFR signaling |
| Q35218182 | RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy |
| Q40030944 | RANK/RANKL expression in prostate cancer |
| Q36491425 | RANK/RANKL pathway in cancer: Biological activity beyond bone? |
| Q90547034 | RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women |
| Q89666841 | RANKL biology: bone metabolism, the immune system, and beyond |
| Q37865171 | RANKL inhibition: a promising novel strategy for breast cancer treatment. |
| Q60406373 | RANKL inhibition—a new weapon against breast cancer? |
| Q42330824 | RANKL inhibitors for osteosarcoma treatment: hope and caution. |
| Q37241264 | RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases |
| Q36253034 | RANKL/OPG in Breast Cancer - Extending Its Territory to BRCA Mutation Carriers |
| Q89967663 | RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies |
| Q37457304 | RANKL/RANK control Brca1 mutation-driven mammary tumors |
| Q37582762 | RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src |
| Q92612736 | RANKL/RANK promotes the migration of gastric cancer cells by interacting with EGFR |
| Q28308042 | RANKL/RANK-beyond bones |
| Q30419245 | RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro |
| Q60917149 | RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives |
| Q28075004 | RANKL/RANK: from bone loss to the prevention of breast cancer |
| Q37725437 | RNPC1 enhances progesterone receptor functions by regulating its mRNA stability in breast cancer |
| Q42486557 | Rankl Impairs Lactogenic Differentiation Through Inhibition of the Prolactin/Stat5 Pathway at Midgestation. |
| Q49371326 | Rankl expression predicts poor prognosis in gastric cancer patients: results from a retrospective and single-center analysis |
| Q35051324 | Receptor activator for nuclear factor-κB ligand signaling promotes progesterone-mediated estrogen-induced mammary carcinogenesis |
| Q34750367 | Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit |
| Q34358320 | Receptor activator of NF-kappaB and podocytes: towards a function of a novel receptor-ligand pair in the survival response of podocyte injury |
| Q91253715 | Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma |
| Q57801311 | Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort |
| Q38747404 | Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657). |
| Q38373935 | Recurrence and metastasis of breast cancer is influenced by ovarian hormone's effect on breast cancer stem cells |
| Q36342182 | Reproductive history and breast cancer risk. |
| Q37207611 | Research resource: progesterone receptor targetome underlying mammary gland branching morphogenesis |
| Q37241255 | Role of RANKL/RANK in primary and secondary breast cancer |
| Q30455154 | Role of denosumab in prostate cancer |
| Q60489259 | Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy |
| Q39090351 | Serum osteoprotegerin and future risk of cancer and cancer-related mortality in the general population: the Tromsø study |
| Q39033091 | Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer |
| Q26799113 | Steroid hormones, steroid receptors, and breast cancer stem cells |
| Q35130819 | Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 |
| Q37634857 | Successful Treatment of Advanced Primary Cutaneous Apocrine Carcinoma on the Scrotum with Systemic Chemotherapy and Radiotherapy Followed by Denosumab |
| Q35598825 | Survival and differentiation of mammary epithelial cells in mammary gland development require nuclear retention of Id2 due to RANK signaling |
| Q38126067 | Systematic review about breast cancer incidence in relation to hormone replacement therapy use. |
| Q33759713 | Targeted treatments of bone metastases in patients with lung cancer |
| Q38081245 | Targeting RANKL in breast cancer: bone metastasis and beyond |
| Q26849690 | Targeting RANKL in metastasis |
| Q38267049 | Targeting the NFκB signaling pathways for breast cancer prevention and therapy. |
| Q98771227 | Targeting the RANKL/RANK/OPG Axis for Cancer Therapy |
| Q57790452 | The Intrinsic and Extrinsic Implications of RANKL/RANK Signaling in Osteosarcoma: From Tumor Initiation to Lung Metastases |
| Q89314569 | The Osteoclast in Bone Metastasis: Player and Target |
| Q52727420 | The Proliferative Response to p27 Down-Regulation in Estrogen Plus Progestin Hormonal Therapy is Lost in Breast Tumors. |
| Q41200607 | The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy. |
| Q95643120 | The RNA binding protein CPEB2 regulates hormone sensing in mammary gland development and luminal breast cancer |
| Q52324737 | The Role of Extracellular Vesicles in Bone Metastasis. |
| Q52620231 | The Role of Steroid Hormones in Breast and Effects on Cancer Stem Cells. |
| Q37745788 | The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. |
| Q53807792 | The association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer. |
| Q35868802 | The biology of progesterone receptor in the normal mammary gland and in breast cancer |
| Q38940135 | The botanical molecule p-hydroxycinnamic acid as a new osteogenic agent: insight into the treatment of cancer bone metastases |
| Q38029394 | The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction |
| Q33768390 | The effects of diet induced obesity on breast cancer associated pathways in mice deficient in SFRP1. |
| Q37655104 | The innovative medicines initiative: a public private partnership model to foster drug discovery |
| Q26799993 | The mammary stem cell hierarchy: a looking glass into heterogeneous breast cancer landscapes |
| Q37619853 | The protective effect of longer duration of breastfeeding against pregnancy-associated triple negative breast cancer |
| Q26783658 | The role of steroid hormones in breast cancer stem cells |
| Q36491430 | The role of the bone microenvironment in skeletal metastasis. |
| Q35820376 | The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype |
| Q26799134 | Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications |
| Q35558919 | Therapeutic targets for bone metastases in breast cancer |
| Q57136184 | Treatment of metastatic bone disease and treatment-induced osteoporosis in prostate cancer |
| Q35194008 | Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling |
| Q30416231 | Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine |
| Q85554027 | Ubiquitin- and ubiquitin-like proteins-conjugating enzymes (E2s) in breast cancer |
| Q28078337 | What Is Breast in the Bone? |
| Q26849473 | Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment? |
| Q89018067 | cIAP2 Is an Independent Signaling and Survival Factor during Mammary Lactational Involution and Tumorigenesis |
Search more.